The U.S. Food and Drug Administration approved a nasal spray, esketamine, to treat depression. The label for the drug will carry a black box warning — the most serious safety warning issued by the FDA. For some patients who have searched for a depression treatment for years, the results of ketamine treatment have been profound. “This offers hope, in capital letters,” said Charney, who is a co-inventor on a patent on the use of ketamine as a depression treatment that has been licensed by Johnson & Johnson. Esketamine, the drug Johnson & Johnson received approval to sell, will appear under the brand name Spravato.

Source: Washington Post March 06, 2019 01:01 UTC